Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesZogenix and astellas announce data published showing the benefits of sumaveltm doseprotm needle-free delivery system
Astellas, 10/23/09
Zogenix, Inc., a privately held pharmaceutical company, and Astellas Pharma US, Inc. announced that positive results from two clinical studies of new SUMAVEL DosePro needle–free delivery system will be published in the November 2009 issue of Headache. SUMAVEL DosePro, was recently approved by the FDA to treat acute migraine, with or without aura, and cluster headache. SUMAVEL DosePro is a first–of–its–kind needle–free delivery system for subcutaneous sumatriptan, a treatment that provides migraine relief within 10 minutes for some patients.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09
Dendreon Receives FDA Acknowledgement of Complete Response
Dendreon Coproration, 11/23/09
ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Companys TAP Technology
ImmunoGen, Inc., 11/20/09
Sponsor
Article Search
Sponsor